Table 2.
Agent | VTD (n = 49) | VTDC (n = 49) | ||
---|---|---|---|---|
n | % | n | % | |
Any subsequent therapy | 24 | 49 | 28 | 57 |
Dexamethasone | 20 | 41 | 21 | 43 |
Lenalidomide | 17 | 35 | 16 | 33 |
Bortezomib | 15 | 31 | 16 | 33 |
Thalidomide | 9 | 18 | 8 | 16 |
Cyclophosphamide | 6 | 12 | 10 | 20 |
Melphalan | 3 | 6 | 8 | 16 |
Doxorubicin | 4 | 8 | 6 | 12 |
VTD, bortezomib‐thalidomide‐dexamethasone; VTDC, bortezomib‐thalidomide‐dexamethasone plus cyclophosphamide.